Revolutionizing Anti-inflammatories for Life

INVEST IN SEN-JAM PHARMACEUTICAL TODAY!

Sen-Jam Pharmaceutical is developing a line of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion dollar market that has seen little innovation in the past 30 years, or since aspirin was invented 125 years ago. We are developing 12 different drugs targeting 7 therapeutic areas intended to reduce pain and inflammation by harnessing your body’s immune system, at the very beginning of the inflammatory cascade. We seek to prevent acute inflammation, slow the progression of inflammatory chronic illnesses, and improve health span. According to our research, there are no pharmaceutical products available to the consumer, either Over-the-Counter (OTC) or prescription (Rx), that acts so early, and safely, at the very beginning of inflammation. Our initial drugs are pre-market, patented, and will seek FDA-approval. Sen-Jam is currently enrolling patients in our covid oral therapeutic Phase 2 Clinical Trial in collaboration with Duke University. Sen-Jam is also ready to begin our Phase 2 clinical trial for prevention of alcohol’s toxic effects. Because we repurpose small molecules with over 30 years of safety data, we are able to bring these new pharmaceuticals to the consumer rapidly, using an accelerated FDA pathway for approval.
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Sen-Jam Pharmaceutical

REASONS TO INVEST

Reasons Icon

We are harnessing the technology of mast cell modulators (the very beginning of the inflammatory/immune cascade) to boldly introduce to the consumer a safer more effective approach to reducing inflammation, before it leads to chronic illness. Sen-Jam is a human-first revolution in the Trillion Dollar anti-inflammatory market that seeks to improve health span.

Reasons Icon

Our drugs are designed to have widespread applications, from covid-19 treatment to opioid withdrawal, alcohol hangovers, arthritis, and vaccine administration (all interconnected by inflammation) amounting to a total addressable market estimated at $217 billion. Because our drugs are safe, some will be OTC; some will be introduced as Rx and we will seek to have them join the OTC arena, to increase accessibility and decrease cost to the consumer; some drugs will be injectable for urgent hospital use.

Reasons Icon

We are led by a team of entrepreneurs, innovators, scientists and futurists with decades of experience in operations and pharmaceuticals, as well as a combined $730 million in successful exits.

Revolutionizing Inflammatory and Pain Management So Humanity Can Thrive


At Sen-Jam Pharmaceuticals, we believe we are reconstructing and disrupting the entire anti-inflammatory market with a suite of drugs ranging from OTC to Rx that embrace mast cell modulators as the future of anti-inflammatory relief. We reformulate safe, trusted drug compounds, some that are currently unavailable, orally, in the United States, to improve clinical outcomes for patients battling opioid use disorder, viral respiratory infections, acute and chronic inflammatory conditions, and even the infamous hangover.  



According to our research, we are the only company pursuing a more gentle mast cell modulator as a path to anti-inflammation, for everyday needs. 

The Problem & Our Solution


Empowering Consumers to Reclaim Their Pain and Inflammation Management


Rising rates of arthritis, the ongoing Covid-19 pandemic, the opioid crisis, and premature aging are all interconnected by rampant inflammation. As a result, American life expectancy has dropped by two years since 2020 (source). Meanwhile, major pharmaceutical companies have lost the trust of consumers when it comes to pain relief after the opioid crisis. Yet, a new oral anti-inflammatory pain reliever has not been introduced to the consumer in over 30 years.  Consumers who are determined to lower their individual inflammation, have resorted to clinically untested alternatives. 


We combined common, safe chemical compounds from two distinct categories of anti-inflammatories, to create a line of drugs designed to take a better approach to combat inflammation. In our research, we found these molecules reduce the rate at which immune system cells called mast cells release proteins that cause inflammation. This approach stops inflammation at the immediate root source, the very beginning of the inflammatory cascade, preventing the long-term tissue damage that causes many health problems.  We believe we have created the most potent, oral, anti-inflammatory drugs with the least side effects, with over 30 years of safety data. 



The Market & Our Traction


Game-Changing Treatments in Multiple Major Markets


We have designed twelve products targeting seven different therapeutic areas, ranging from over-the-counter to prescription strengths, often with multi-use, multi-organ applications. As a result, Sen-Jam Pharmaceuticals has the potential to reach patients in multiple major markets, including arthritis, respiratory infections, Covid therapeutics, opioid withdrawal, vaccine administration, and even alcohol hangovers. That makes our total addressable market an estimated $217 billion. 


(source, source, source, source, source, source, source



Since our launch, we have achieved the following milestones: 


Because we are repurposing existing small molecules, we plan to fast-track our regulatory pathway via 505(B)2 FDA approval. Meanwhile, our international patents provide a wide wingspan for global commercialization.


Why Invest


Developing the Next Generation of Anti-Inflammatory Drugs



We call ourselves the Good Karma Pharma People because our mission is to use innovation and transparency to improve societal well-being across the globe. Over the next few years, we plan to leverage our operational excellence and evidence-based science to advance our anti-inflammatory therapeutics to commercialization - all while expanding our asset base and global licensing. 


We will be using some of the funds from this raise towards:


*For a full description of the use of proceeds from this offering please see the Use of Proceeds section of the Offering Memorandum


With patented technology, diverse use cases across multiple billion-dollar markets, and strong strategic partnerships, we are ready to build the future of anti-inflammatory treatments, bringing everyone a much-needed solution. 







Bold (⌘B)
Code View
Code View

ABOUT

HEADQUARTERS
35 Fort Hill Drive
Lloyd Harbor, NY 11743
VALUATION
$69.98M
PREVIOUSLY CROWDFUNDED
$1M

Sen-Jam Pharmaceutical is developing a line of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion dollar market that has seen little innovation in the past 30 years, or since aspirin was invented 125 years ago. We are developing 12 different drugs targeting 7 therapeutic areas intended to reduce pain and inflammation by harnessing your body’s immune system, at the very beginning of the inflammatory cascade. We seek to prevent acute inflammation, slow the progression of inflammatory chronic illnesses, and improve health span. According to our research, there are no pharmaceutical products available to the consumer, either Over-the-Counter (OTC) or prescription (Rx), that acts so early, and safely, at the very beginning of inflammation. Our initial drugs are pre-market, patented, and will seek FDA-approval. Sen-Jam is currently enrolling patients in our covid oral therapeutic Phase 2 Clinical Trial in collaboration with Duke University. Sen-Jam is also ready to begin our Phase 2 clinical trial for prevention of alcohol’s toxic effects. Because we repurpose small molecules with over 30 years of safety data, we are able to bring these new pharmaceuticals to the consumer rapidly, using an accelerated FDA pathway for approval.

TEAM

James Iversen
James Iversen
CEO, Co-Founder & Director

Executive with a consistent track record of designing + executing business strategies that deliver rapid growth in sales, profits, market share + customer satisfaction. Client remits include start-ups to late stage, often resulting in M&A transaction

Jacqueline M. Iversen
Jacqueline M. Iversen
Chief Clinical Officer, Co-Founder & Secretary

Jackie has extensive knowledge + capabilities in a multitude of clinical settings. Her expertise involves providing clinical pain education + having completed a research fellowship in pharmacokinetics + pain at Memorial Sloan Kettering Cancer Center.

Neal Zahn

Neal Zahn

Director of Global Licensing

Wildly successful and seasoned executive in the manufacturing, operations and pharmaceutical industries. Strong bench of skills in the business development space and has fine tuned his legendary resourcefulness in building long lasting, high impact strategic alliances. Charming and unflappable, bringing optimism and pragmatism to the global stage.

Christine Leonard

Christine Leonard

Head of Strategic Communications

Christine is a highly respected and award-winning marcom strategist with passion for brands that aim to improve lives. She has led marketing, consumer insight mining and communications development for world class healthcare companies big and small. She was involved with launching the global Blockbuster brand Dupixient and has a keen understanding of driving success in commerce with both healthcare professionals and consumers across many inflammatory brands.

Tom Dahl

Tom Dahl

Head of Product Development and Regulatory Affairs

Accomplished biotech/ pharmaceutical executive with deep expertise in early stage ventures, including technical analysis of products and technologies, business strategy and operations, development, clinical trial design and interpretation. Tenacious and well connected, helping to drive successful outcomes in both the clinical and regulatory arenas.

Alexander Wissner-Gross

Alexander Wissner-Gross

Advisor

Dr. Alexander D. Wissner-Gross is an award-winning scientist, inventor, entrepreneur, and angel investor. He serves as President and Chief Scientist of Gemedy and holds academic appointments at the Harvard Institute for Applied Computational Science, the Harvard Innovation Lab, and the MIT Media Lab. He has received 123 major distinctions, authored 18 publications, been granted 23 issued, pending, and provisional patents, and founded, managed, and advised 7 technology companies, 3 of which have been acquired. A popular TED speaker, his talks have been viewed almost 2 million times and translated into 27 languages. His work has also been featured in more than 180 press outlets worldwide including The New York Times, CNN, USA Today, the Wall Street Journal, and BusinessWeek.

TERMS

Sen-Jam Pharmaceutical
Overview
PRICE PER SHARE
$7.35
DEADLINE
Jan 12, 2023
VALUATION
$69.98M
AMOUNT RAISED
$73,636.46
Breakdown
MIN INVESTMENT
$294.00
MAX INVESTMENT
$1,007,192.55
MIN NUMBER OF SHARES OFFERED
1,360
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
543,237

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Sen-Jam Pharmaceutical Inc.

Corporate Address

:

35 Fort Hill Drive, Lloyd Harbor, NY 11743

Offering Minimum

:

$9,996.00

Offering Maximum

:

$3,992,791.95

Minimum Investment Amount

(per investor)

:

$294.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

1,360

Maximum Number of Shares Offered

:

543,237

Price per Share

:

$7.35

Pre-Money Valuation

:

$69,979,019.25











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of his or her authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Transfer Restrictions Applicable to Securities Sold in this Offering

Section 7.1(a) of bylaws of the Company (the “ByLaws”) details the right of first refusal (“ROFR”) restriction applicable to the Common Stock sold in this offering. In short, if a selling stockholder receives a bona fide offer from a third party to purchase all or any portion of such stockholder’s shares of stock and the selling stockholder wishes to accept such offer, the selling stockholder must first provide Sen-Jam with prompt written notice (“Sale Notice”). Upon receipt of such notice, Sen-Jam may elect to purchase the shares or waive its purchase right, all subject to the procedures and applicable notice periods, as detailed in Section 7.1(a) of the Bylaws.

Section 7.2 (a) - (g) of the Bylaws provides for additional transfer restrictions, including but not limited to: (1) ineligible transferee; (2) competitor transferees; (3) the transfer would result in a breach of laws or regulations if consummated; (4) the transfer would result in the corporation or its stockholders incurring liability; (5) the transfer would result in a registration or filing requirement on behalf of the Company; (6) the transfer would result in a loss of federal or state exemption; and (7) the transfer or the transferee would be harmful or injurious to the business or reputation of the Company. Each of the foregoing will be enforced by the Board of Directors of the Company (the “Board”) in its sole discretion.

Section 7.3 of the Bylaws details exemptions to the transfer restrictions of Sections 7.1 and 7.2 of the Bylaws.

Drag-Along Right Applicable to Securities Sold in this Offering

Section 7.5 of the Bylaws provides for a Drag-Along Right. In short, if the Board votes to approve any sale or change in control of the Company, then each stockholder must consent to, and agree to raise no objections against, such transaction and take all necessary or desirable actions to facilitate the consummation of such transaction as requested by the Company. Additional obligations and information are outlined in Section 7.5 (a)-(c) of the Bylaws.

SJP Owner Network Bonus (Loyalty Bonus)

The Company would like to offer you an additional 10% bonus shares of your total investment.

Time-Based:

Friends and Family

Invest within the first week and receive 15% bonus shares

Super Early Bird Bonus

Invest in the second week and receive 10% bonus shares

Early Bird Bonus

Invest in the third week and receive 5% bonus shares

Amount-Based:

$1,000+│ Tier 1

The Company would like to offer you an additional 3% bonus shares of your total investment.

$5,000+ │ Tier 2

The Company would like to offer you an additional 7% bonus shares of your total investment.

$10,000+ │ Tier 3

The Company would like to offer you an additional 10% bonus shares of your total investment.

$20,000+ │ Tier 4

The Company would like to offer you an additional 12% bonus shares of your total investment.

$25,000+ │ Tier 5

The Company would like to offer you an additional 15% bonus shares of your total investment.

$50,000+ │ Tier 6

The Company would like to offer you an additional 20% bonus shares of your total investment.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners’ Bonus

The Company will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owner’s bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example (assuming no other eligible bonuses), if you buy 100 shares of Common Stock at $7.35 / share, you will receive 110 shares Common Stock, meaning you’ll own 110 shares for $735. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the Company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the SJP Owner Network Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative.

ALL UPDATES

12.05.22

Our Community Joins In! | Insider Investment Notice

We're excited to see our community come in and invest in Sen-Jam Pharmaceutical!

Our Insiders have invested a total of $20,044.05 into the offering to date!

We hope you join in as well! Invest in Sen-Jam Pharmaceutical.

Be well, safe, and inspired,

Jim

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.

11.22.22

Why Our lead Strategic Investor Decided to Partner with Us to Disrupt the Pharma Industry

On November 10th, we held a Fireside Chat Webinar entitled "Are You A Disruptor?"  Many of you attended live (thank you!).  But one of our favorite moments was when Kiran Vepuri from KVK Tech shared his point of view on why Sen-Jam Pharmaceutical was a fantastic partnership with his firm and within the spirit of disruption.


If you'd like to see the whole 50 minute Fireside Chat, please click HERE.

We could not be more proud of our alliance with KVK Tech and even spent several days just last week in person at their pristine facility to see the incredible progress they are making in engineering our oral COVID-19 therapeutic.  Here is a photo from a few days ago.

The advances continue and we are thrilled to see these milestone achieved with such like-minded partners like KVK Tech.

11.18.22

Top 5 Reasons to Invest in Sen-Jam!

Have less than two and half minutes to learn something valuable and maybe even bring a bright moment of entertainment to your day?  Check out our video on the Top Five Reasons to Invest in Sen-Jam Pharmaceutical.  Thanks and Happy Wednesday!  Brighten a friend or colleagues day too and consider forward this email to them!  


11.09.22

Understanding The Balancing Act Around Vaccines

This article, by Sen-Jam Pharmaceutical Founder and Head of Clinical Development, Jackie Iversen RPh MA, was published a week ago in Pharmacy Times.  See the Article HERE or read it in full below.


As pharmacists, it’s important to understand and embrace the science and the tools that COVID-19 has brought.

Vaccines are becoming a greater part of our future beyond the typical annual flu shot of years past. Most often, sea change events in our world’s history lead to new discoveries and tools being created to counteract life’s challenges. And the COVID-19 pandemic is one of those future-changing events.

As pharmacists, it’s important to understand and embrace the science and the tools that COVID-19 has brought to the fore, because, in my opinion, the pharmacy world is going through a dramatic evolution that will change health forever. As pharmacists, as drug experts, and as consumer-facing providers of information and support, we will be leading and communicating this revolution to everyone.

The elementals of vaccines

Let’s think of vaccines as communication tools. A technology (tool) that can communicate to your adaptive immune system to generate a response. To do so, it must get your adaptive immune system to react (think T and B cells), and then follow through with the message or desired response (production of antibodies). This adaptive immune system reaction is the efficacy part of a vaccine, also called the immunogenicity.

Unfortunately, getting the adaptive immune system’s attention to reactis the adverse effect (AE) part of a vaccine, called the reactogenicity. Reactogenicity is purposefully built into each vaccine, via an effector, which communicates to the innate immune system to mount a fast and broad call to duty against any invading foreign substance or toxin.

The mediators released from the innate immune system communicate to the adaptive immune system that an antigen is present. Therefore, the AE profile of vaccines mimic the broad reaction caused by the innate immune system: site-pain (pain, redness, swelling) and flu-like symptoms (fever, myalgia, headache, or rash). In summary, both the innate and adaptive immune systems must work properly and in concert for the communication tool (vaccine) to produce antibodies.

Going deeper on the vaccine reactivity

Vaccine technology has advanced the immunogenicity science of the equation faster than the reactogenicity science of the equation. This has led to great advancements in the number and types of vaccines, but a lack of options for the consumer to mitigate troublesome AEs.

Based on the mechanism of action of vaccines, there is a belief that reducing the innate immune response with pharmaceutical agents (i.e., acetaminophen, non-steroidal anti-inflammatory drugs, antihistamines) around the time of vaccine administration would reduce immunogenicity. Yet, these studies have not been performed.

Prior to COVID-19, such a study was a large and expensive undertaking because antibody formation was not easily quantified or routinely measured—but COVID-19 has changed this. Currently, COVID-19 vaccine immunogenicity (antibody formation) is frequently measured in individuals to determine dosing schedules.

This change in practice allows manufacturers to quickly assess alternative agents that could be either manufactured into the vaccine as an effector, (i.e., lipid nano particle of mRNA vaccines) or to assess pharmaceutical agents that could safely be administered with vaccines to reduce vaccine AEs.

Why is this important? Because trust is at an all-time low across this country and pharmacists are still revered by the public in terms of being one of the last professional groups people still trust.

Our relationship with our patients is based on this often-fragile measure of trust. Pharmacists across the United States have been instrumental in administering a staggering total of greater than 200 million doses of vaccines in the past 2 years.

This has helped to change the course of COVID-induced injury. Yet, we still have no consistent, scientifically determined, pharmacy advice for reducing the AEs of vaccine administration.

This leaves the pharmacist blindfolded, doing a balancing act between the vaccine manufacturers’ products and their patient’s immune system, which is a very precarious position to be in, and could lead to mistrust, vaccine hesitancy, or non-adherence.

About the Author

Jackie Iversen, RPh, MS, Founder and Head of Clinical Development Sen-Jam Pharmaceutical. Check us out on StartEngine.



11.08.22

Blueprint to a Billion - Unicorn III - Opioid Withdrawal (SJP-005)

Over the last 2 weeks we shared the development progress of Unicorn I, SJP-002C (Oral COVID Therapeutic), Unicorn II, SJP-001 (Alcohol Hangover Prevention), and now it's time to share the development progress with Unicorn III, SJP-005 (Opioid Withdrawal). One Billion in delivered value is equal to 14x's our current pre-money valuation, 2 billion is equal to 28x's our current pre-money valuation, and now 3 billion is equal to 33x's our current pre-money valuation. 

Sen-Jam prides itself on a powerful mission of improving societal wellbeing by creating therapeutics that are safe, efficacious, and accessible by all. We operate in an environment of Transparency, Passion, and Grit. We are the Good Karma Pharma People!

Starting with the End in Mind, let me unpack our "Blueprint to a Billion" for SJP-005.  The number one reason individuals stay addicted to opioids is the pain of withdrawal is too severe. Unfortunately, there are limited therapeutics to effectively address this issue. The most popular treatment is to trade short acting opioids for longer acting opioids like methadone and buprenorphine (Brand name Suboxone). Although these drugs have been known to save lives, there is also a withdrawal when trying to tapper off these treatments. It's our goal to address the withdrawal signs at every stage with the hope of helping individuals become opioid independent. 

After our early research we conducted multiple in-vivo studies resulting in the publication of two papers:

The results of this work showed we can reduce Opioid Withdrawal signs and duration by 50% and that SJP-005 was opioid sparring when combined with an opioid, i.e. less opioid was required to get the same level of pain relief thereby reducing the likelihood of addiction.

We have recently been contacted by an independent 3rd party that is interested in conducting an Investigator Initiated Study to test the effectiveness of SJP-005 in reducing the daily requirements of Suboxone. 

We believe SJP-005 will be a market disruptor with the following key points of differentiation:

  • Cost vs. current standard of care 
  • Safety (Known drugs with long history of safety and negligible drug:drug interaction )
  • Non-opioid pain reliever
  • Efficacy (verified by the FDA)
  • Accessible (other therapeutics require driving daily to a clinic or finding a physician authorized to prescribe specialized treatment) 

We are projecting 7.5% market penetration of this small subset of patients (600,000) with projected growth to 40%. This represents a small fraction of the projected 15M people prescribed opioids annually. Our projected dose regimen price results in revenue of $891M by year 16 with a current risk-adjusted Net Present Value (rNPV) of $261M and future $1.4B upon NDA approval.

"Never underestimate the power of a small group of committed people to change the world. In fact, it is the only thing that ever has." - Margaret Mead

The Clinical Development Plan will be driven by our ability to open an Investigational New Drug (IND) application and raise the capital to fund the Clinical Trial. We believe we will benefit from the results of our Phase 1/2 Clinical Trial for our Oral COVID therapeutic (SJP-002C), allowing us to possibly start this trial in Phase 2.

                                Market Analysis & Valuation complete by Destum Partners and not validated by StartEngine

In 2018, we identified that 3M people were suffering from Opioid Use Disorder of which 40% were actively seeking treatment and 50% had access to treatment, resulting in a Target Population of 600,000. This is a small target population. Yet, it is estimated that 10 million Americans are on chronic opioid therapy, defined as opioid use 24 hours a day for more than 90 consecutive days. If these chronic opioid patients sought to reduce or cease opioid use, they too would be in search of a product like ours, as they experience withdrawal symptoms. The 600,000 is only scratching the surface of the market need.

                                 Market Analysis & Valuation complete by Destum Partners and not validated by StartEngine

Risk-Adjusted Net Present Value increases significantly as de-risking occurs during Clinical Development. Intellectual Property: Patents have been granted in the United States for Opioid Tolerance & Dependence. Patents are still pending in the United States, Europe, Canada, & Australia for Withdrawal, Tolerance, & Dependence.

The combination of an effective treatment and mental health support is what is required to help reduce dependency. 

Thank you for your continued support!

Jim

11.04.22

Your Invitation to the “Are You A Disruptor?” Fireside Chat


Hello Investors and Friends of Sen-Jam Pharmaceutical,


Are you a disruptive force for good?


Join us on Thursday, November 10th from 9-10am PT/ 12-1 pm ET for "Are You A Disruptor?"


This fireside chat will be packed with insights on how the CEO of Sen-Jam Pharmaceutical and Real Leaders Impact Collaborative member, Jim Iversen, has strategically used collaboration, funding, and design to disrupt the pharmaceutical industry.  He will be joined by Kiran Vepuri, Vice President of Business Development and Brand Marketing at KVK Tech.


We will discuss:

  • How Smart Innovators Find Pathways Forward
  • Community Impact and Cultivating Healthy Communities
  • The Importance of Community Funding and Strategic Collaboration
  • Designing Product to Support 8 Billion People


The chat will conclude with an interactive Q&A session, so please come with your questions or submit them in advance.


Be sure to save your spot!

RSVP

Can't make it? Consider forwarding this email to a peer who would benefit.


Hope to see you there!

11.01.22

Our Community Joins In! | Insider Investment Notice

Dear Sen-Jam Champions,

We're excited to see our community come in and invest in Sen-Jam

Our Insiders have invested a total of $15,534.01 into the offering to date!

We hope you join in as well! Invest in Sen-Jam

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.

Please let me know if you have any questions! 


Jim

11.01.22

Blueprint to a Billion - Unicorn II - Reducing Inflammation Associated with Alcohol Consumption (SJP-001)

Sen-Jam Community,

Last week we shared the development progress of Unicorn I, SJP-002C (Oral COVID Therapeutic) . Now it's time to share the development progress with Unicorn II, SJP-001 (Alcohol Hangover Prevention). One Billion in delivered value is equal to 14x's our current pre-money valuation. Two Billion in delivered value is equal to 28x's our current pre-money valuation. 

Sen-Jam prides itself on a powerful mission of improving societal wellbeing by creating therapeutics that are safe, efficacious, and accessible by all. We operate in an environment of Transparency, Passion, and Grit. We are the Good Karma Pharma People!

Starting with the End in Mind, let me unpack our "Blueprint to a Billion" for SJP-001.  Alcohol causes acute inflammation. Acute inflammation over time causes chronic inflammation and disease. If we can reduce inflammation, we can reduce disease.  How do we know our product reduces inflammation? No hangover after taking SJP-001. Hangover is a side effect of inflammation!

Worldwide alcohol sales are projected to top $2.4 Trillion in 2025. Cleary, alcohol is enjoyed by many. When unchecked inflammation associated with alcohol consumption is associated with health loss from several diseases including liver cirrhosis, breast cancer, & tuberculosis resulting in the 1.8 million deaths in 2020.

We believe SJP-001 will be a market disruptor with the following key points of differentiation:

  • Price ($2.89(wholesale)/$4.99(Retail)/dose regimen 
  • FDA (OTC) approved for the prevention of alcohol hangover
  • Safety (Known drugs with long history of safety and negligible drug:drug interaction )
  • Patented
  • Over-the-Counter allowing for mass distribution

We are projecting 3% market penetration of drinking experiences worldwide and believe this could go as high as 10% of drinking experiences as further research highlights the benefits of reducing inflammation associated with alcohol consumption. Our projected dose regimen price results in revenue of $1.1B in 2040 with a current risk-adjusted Net Present Value (rNPV) of $360M and future $1.4B (2025).

"Vision without action is a daydream. Action without vision is a nightmare." - Japanese proverb

Intellectual Property: Patents have been granted in United State, Europe, Japan, Australia, Mexico, & South Africa. Patents are still pending in Korea, Canada, Israel, Brazil, & New Zealand. 

We have an open Investigational New Drug (IND) Application (132098) with the FDA to begin our phase 2 clinical trial. Our plan is to get FDA approval in the US and conduct bridging studies in other countries for approval.  

The revenue forecast is based on selling finished product through distributors and direct to consumer and may change if we license the Intellectual Property and Formulation.

Risk-Adjusted Net Present Value increases significantly as de-risking occurs during Clinical Development. 

Keep an eye out for additional Blueprint to a Billion publications for some of our other assets including Unicorn III - Opioid Withdrawal (SJP-005). 

Thank you for your continued interest and support!

Jim

10.27.22

Sen-Jam Pharmaceutical Essentials

Sen-Jam Champions,

Two essentials when considering joining the  Sen-Jam movement:

. Changing the World for Good (1 minute Video)

. Our plan to make it happen (Pitch Deck)

As a reminder, our Early Bird Special Bonus ends at 12pm (EST) next Thursday, November 3rd!

Thank you for joining us on this journey.

Jim



10.25.22

Blueprint to a Billion! Starting with the End in Mind...

Sen-Jam Community,

We want to share part 1 of our 3 part series on our lead assets, Blueprint to a Billion. 

Vision, Strategy, & Leadership provides the destination, roadmap, and execution to turn ideas into reality.  We are focused on Community Fundraising to advance Community Supportive Therapeutics resulting in positive Community Impact.

I'm so proud of the work we are doing at Sen-Jam and I believe we have 3 assets currently under development that have the potential of delivering a Billon dollars in value to our shareholders; SJP-002C (Oral COVID Therapeutic), SJP-001 (Alcohol Hangover Prevention), and SJP-005 (Opioid Withdrawal). 

Sen-Jam prides itself on a powerful mission of improving societal wellbeing by creating therapeutics that are safe, efficacious, and accessible by all. We operate in an environment of Transparency, Passion, and Grit. We are the Good Karma Pharma People!

Starting with the End in Mind, let me unpack our "Blueprint to a Billion" for SJP-002C. COVID is not going away soon. There are limited tools in the tool kit. Pfizer's Paxlovid, is projected to generate $22B in revenue in 2022 which helps to define the Total Addressable Market (TAM) currently. 

We believe SJP-002C will be a market disruptor with the following key points of differentiation:

  • Cost ($80/dose regimen vs. $530/dose regimen (Paxlovid))
  • Safety (Known drugs with long history of safety and negligible drug:drug interaction )
  • Broader spectrum therapeutic for anticipated future variants and mutations 
  • Ease of distribution (Unique formulation allowing for coated beads to be shipped throughout the world for encapsulation and local distribution)

We expect our efforts to be rewarded with 10-30% of the future oral COVID therapeutic market. At our projected dose regimen cost this could result in $335M to $1B in revenue. Public company valuation (3.0x Revenue) for specialty pharma would value our one asset at $1B to $3B.  We expect the possible sale of this asset within 12 months from now, after successfully completing our Phase 2 clinical study with Duke University Medical Center, completing the Formulation and CMC submission to the FDA, and securing 3-5 licensees around the world for encapsulation and distribution.

"Good business leaders create a vision, articulate the vision, passionately own the vision, and relentlessly drive it to completion." - Jack Welch


Jackie Iversen, Founder & Chief Clinical Officer presenting Mechanism of Action of SJP-002C to the Executive Team at KVK Tech.


KVK Tech walking us through the R&D process for Formulation validation


KVK Tech walking us through how the core of our bead is developed. 


Jackie and I taking control of the machine that will layer our therapeutic onto the bead.


Our coated beads move to a clean and controlled environment for encapsulation.


KVK explaining the encapsulation process. This machine can make 1M capsules per 8 hour shift. That's 35 capsules per second.


R&D batches of our oral COVID therapeutic SJP-002C.  Note the beads. They have each been coated with the 2 components of our therapeutics and a hardened outer shell. This will allow us to ship the beads worldwide to contract manufacturing partners for encapsulation and local distribution. Final capsule color to be yellowish orange.



Our Team: (L-R) Christine Leonard - Head of Strategic Communication, KVK Executive, Dana Erwin - Investor, Dr. Thomas Dahl - Head of Product Development & Regulatory Affairs, Jackie Iversen - Founder & Chief Clinical Officer, Jim Iversen - CEO, Neal Zahn - Head of Global Licensing, & KVK Executive.

If not us, then who? If not now, then when? We are one! Let's do this...

Thank you for your continued interest and support!

Jim 










Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Sen-Jam Pharmaceutical.

$294.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,000.00

Tier 1

The Company would like to offer you an additional 3% bonus shares of your total investment.

$5,000.00

Tier 2

The Company would like to offer you an additional 7% bonus shares of your total investment.

$10,000.00

Tier 3

The Company would like to offer you an additional 10% bonus shares of your total investment.

$20,000.00

Tier 4

The Company would like to offer you an additional 12% bonus shares of your total investment.

$25,000.00

Tier 5

The Company would like to offer you an additional 15% bonus shares of your total investment.

$50,000.00

Tier 6

The Company would like to offer you an additional 20% bonus shares of your total investment.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.